Axium adds new drugs to HepVisions therapy management program
LAKE MARY, Fla. — Specialty pharmacy provider Axium Healthcare Pharmacy has introduced two recently approved hepatitis C drugs to its HepVisions therapy management program, the company said Thursday.
Axium announced the addition of Merck ’s Victrelis (boceprevir) and Vertex Pharmaceuticals’ Incivek (telaprevir) to the program, through which it provides comprehensive compliance support, patient education, side effect management, clinical interventions and communication with the patient and physician.
“Axium is pleased to add Victrelis and Incivek to the HepVisions program,” Axium president and CEO Mark Montgomery said. “The new triple therapy regimen is complex and expensive. Careful patient education, monitoring and adherence are keys to successful treatment.”
Both of the drugs are approved for use in a triple therapy that includes pegylated interferon, a type of biotech drug used for hepatitis C, and ribavirin, a generic antiviral.